1. Home
  2. AKRO vs GVA Comparison

AKRO vs GVA Comparison

Compare AKRO & GVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • GVA
  • Stock Information
  • Founded
  • AKRO 2017
  • GVA 1922
  • Country
  • AKRO United States
  • GVA United States
  • Employees
  • AKRO N/A
  • GVA N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • GVA Military/Government/Technical
  • Sector
  • AKRO Health Care
  • GVA Industrials
  • Exchange
  • AKRO Nasdaq
  • GVA Nasdaq
  • Market Cap
  • AKRO 3.9B
  • GVA 4.1B
  • IPO Year
  • AKRO 2019
  • GVA 1990
  • Fundamental
  • Price
  • AKRO $45.02
  • GVA $107.14
  • Analyst Decision
  • AKRO Strong Buy
  • GVA Strong Sell
  • Analyst Count
  • AKRO 8
  • GVA 1
  • Target Price
  • AKRO $80.38
  • GVA $76.00
  • AVG Volume (30 Days)
  • AKRO 856.3K
  • GVA 628.0K
  • Earning Date
  • AKRO 08-08-2025
  • GVA 10-30-2025
  • Dividend Yield
  • AKRO N/A
  • GVA 0.48%
  • EPS Growth
  • AKRO N/A
  • GVA 70.18
  • EPS
  • AKRO N/A
  • GVA 3.11
  • Revenue
  • AKRO N/A
  • GVA $4,078,324,000.00
  • Revenue This Year
  • AKRO N/A
  • GVA $12.76
  • Revenue Next Year
  • AKRO N/A
  • GVA $9.12
  • P/E Ratio
  • AKRO N/A
  • GVA $34.67
  • Revenue Growth
  • AKRO N/A
  • GVA 7.17
  • 52 Week Low
  • AKRO $21.34
  • GVA $69.08
  • 52 Week High
  • AKRO $58.40
  • GVA $112.16
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 38.25
  • GVA 55.42
  • Support Level
  • AKRO $43.08
  • GVA $105.13
  • Resistance Level
  • AKRO $46.18
  • GVA $112.16
  • Average True Range (ATR)
  • AKRO 1.62
  • GVA 1.86
  • MACD
  • AKRO -0.30
  • GVA -0.88
  • Stochastic Oscillator
  • AKRO 29.56
  • GVA 28.31

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

About GVA Granite Construction Incorporated

Granite Construction Inc engages in the construction and development of various infrastructure projects on behalf of public and private clients in the United States. It focuses on heavy civil infrastructure projects, including roads, highways, transit facilities, airports, bridges, and other infrastructure projects. In addition, the company performs site preparation and infrastructure services for residential development, energy development, and other facilities. The majority of revenue is derived from the company's Construction operating segment, with the remainder derived from its Materials segment.

Share on Social Networks: